Belfast Telegraph

Friday 22 August 2014

New treatment could aid sufferers of rare cancer

People with a rare form of cancer which occurs in the muscles, nerves, fat or blood vessels could benefit from a new treatment, it was announced today.

The National Institute for Health and Clinical Excellence (Nice) has reversed an earlier decision on the drug trabectedin after the manufacturers agreed to a cost-reducing scheme.

Under the plan, the firm PharmaMar will meet the cost of the drug if it is needed beyond a fifth cycle of treatment.

The medicine could extend the lives of people with advanced soft tissue sarcoma by at least three months.

Trabectedin will benefit around 110 patients a year who have failed on other treatments, at a cost of more than £3,500 a cycle.

The drug, which is given intravenously, works by altering the DNA in cancer cells, which stops them growing and spreading.

COMMENT RULES: Comments that are judged to be defamatory, abusive or in bad taste are not acceptable and contributors who consistently fall below certain criteria will be permanently blacklisted. The moderator will not enter into debate with individual contributors and the moderator’s decision is final. It is Belfast Telegraph policy to close comments on court cases, tribunals and active legal investigations. We may also close comments on articles which are being targeted for abuse. Problems with commenting? customercare@belfasttelegraph.co.uk

Latest News

Latest Sport

Latest Showbiz